Home Biosimilar Antibodies Others Others Anetumab (Anti-Mesothelin)
For research use only. Not for use in humans.

Anetumab (Anti-Mesothelin)

Synonyms: Anti-MSLN Antibody

Anetumab (Anti-Mesothelin) is an antibody targeting mesothelin (MSLN). It can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC) and can be used for the research of malignant tumor. MW :143.8 KD.

Anetumab (Anti-Mesothelin)

Quality Control

Batch: A267301 Purity: 99% Protein concentration: 7.73mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Anetumab (Anti-Mesothelin) is an antibody targeting mesothelin (MSLN). It can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC) and can be used for the research of malignant tumor. MW :143.8 KD.
References

Product Details

CAS No. 1954758-84-9
Molecular Weight 143.8
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06885697 RECRUITING Drug: cyclophosphamide|Drug: fludarabine Mesothelioma; Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Ovarian Neoplasms; Lung Neoplasms; Thymus Neoplasms; Colonic Neoplasms National Cancer Institute (NCI) 2025-07-08 PHASE1
NCT03816358 ACTIVE_NOT_RECRUITING Drug: Gemcitabine Hydrochloride Pancreatic Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8 National Cancer Institute (NCI) 2019-12-09 PHASE1
NCT03587311 ACTIVE_NOT_RECRUITING Drug: Paclitaxel Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma National Cancer Institute (NCI) 2018-10-12 PHASE2
NCT07010523 RECRUITING Drug: Fludarabine|Drug: Cyclophosphamide Mesothelin-positive Advanced Malignant Solid Tumors First Affiliated Hospital of Zhejiang University 2024-10-15
NCT05848999 UNKNOWN Mesothelin-positive Advanced Malignant Solid Tumors Zhejiang University 2023-04-27 PHASE1
NCT05531708 WITHDRAWN Drug: Fludarabine|Drug: Cyclophosphamide Mesothelin-positive Advanced Refractory Solid Tumors Shanghai Pudong Hospital 2021-04-02 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-08-26)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.